Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lipo-PGE1 for Renal Hypoxia in Diabetic Nephropathy and CKD
NCT02628106Phase 4Completed
- Sponsor
- West China Hospital of Sichuan University
- Start
- Dec 2015
- Primary completion
- Jan 2016
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Alprostadil Liposomes for Injection in diabetic nephropathy (DN) and chronic kidney disease (CKD), sponsored by West China Hospital of Sichuan University. Primary endpoint: Change of Tissue Content of Deoxyhemoglobin Assessed by BOLD-MRI at 14 days. Started Dec 2015; status: completed.
02
Drugs
Alprostadil Liposomes for Injection
03
Conditions
diabetic nephropathy (DN)chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT02628106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02628106.